VYROLOGIX
Dead / Abandoned — Abandoned — no statement of use filed (as of 05 Sept 2022)
What this means for you
This application is over — abandoned 05 Sept 2022. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88877284
- Mark type
- Word mark
- Filed
- 17 Apr 2020
- Published for opposition
- 08 Dec 2020
- Abandoned
- 05 Sept 2022
- Attorney of record
- Jared M. Barrett
Goods and services
- Class 005 — Pharmaceuticals: therapeutic preparations, namely, antibodies for use in targeting the CCR5 cell receptor, for preventing and/or treating HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, respiratory diseases and disorders; therapeutic preparations for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, respiratory diseases and disorders; therapeutic preparations for the treatment of COVID-19
Owner
- CytoDyn Inc., Vancouver, WA, US
- CytoDyn Inc., Vancouver, WA, US
Prosecution history
- 06 Sept 2022 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 05 Sept 2022 — ABANDONMENT - NO USE STATEMENT FILED
- 01 Feb 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 28 Jan 2022 — SOU EXTENSION 2 GRANTED
- 28 Jan 2022 — SOU EXTENSION 2 FILED
- 28 Jan 2022 — SOU TEAS EXTENSION RECEIVED
- 15 Jul 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 13 Jul 2021 — SOU EXTENSION 1 GRANTED
- 13 Jul 2021 — SOU EXTENSION 1 FILED
- 13 Jul 2021 — SOU TEAS EXTENSION RECEIVED
- 02 Feb 2021 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 08 Dec 2020 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 08 Dec 2020 — PUBLISHED FOR OPPOSITION
- 18 Nov 2020 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 03 Nov 2020 — APPROVED FOR PUB - PRINCIPAL REGISTER